Resources, contacts and background information for journalists, analysts and conference organisers covering data integrity, biotech infrastructure and the organisations we work with.
We aim to respond to journalist enquiries within one working day . For urgent or deadline-sensitive enquiries, please mark the email URGENT in the subject line.
Use either the short or long version verbatim, or adapt as needed. Copy buttons below each paragraph for convenience.
The BioChain provides the infrastructure layer that makes biological data secure, traceable and audit-ready for organisations operating in regulated environments. Founded in 2025 with headquarters in Oxford and European R&D in Ghent, the platform supports organisations across genomic research, livestock biosecurity and life sciences, with deployments designed to meet the principles underpinning 21 CFR Part 11, EU Annex 11 and equivalent regulatory frameworks.
The BioChain was established in 2025 to address a structural gap in regulated industries: while data integrity has long been a regulatory expectation, the underlying systems that capture, store and move biological data were rarely designed with integrity as a first-order property. As regulators have hardened their expectations — through interpretation of frameworks including 21 CFR Part 11, EU Annex 11, and MHRA GxP Data Integrity guidance — organisations have been left exposed by infrastructure that cannot produce the evidence regulators now require.
The BioChain platform addresses this by providing verifiable, tamper-evident records that preserve data sovereignty and privacy. The architecture keeps sensitive payloads in client-controlled storage while making integrity continuously verifiable across institutions and jurisdictions, without requiring organisations to rebuild their existing systems.
The BioChain provides the infrastructure layer that makes biological data secure, traceable and audit-ready for organisations operating in regulated environments. Founded in 2025 with headquarters in Oxford and European R&D in Ghent, the platform supports organisations across genomic research, livestock biosecurity and life sciences, with deployments designed to meet the principles underpinning 21 CFR Part 11, EU Annex 11 and equivalent regulatory frameworks.
The BioChain was established in 2025 to address a structural gap in regulated industries: while data integrity has long been a regulatory expectation, the underlying systems that capture, store and move biological data were rarely designed with integrity as a first-order property. As regulators have hardened their expectations — through interpretation of frameworks including 21 CFR Part 11, EU Annex 11, and MHRA GxP Data Integrity guidance — organisations have been left exposed by infrastructure that cannot produce the evidence regulators now require.
The BioChain platform addresses this by providing verifiable, tamper-evident records that preserve data sovereignty and privacy. The architecture keeps sensitive payloads in client-controlled storage while making integrity continuously verifiable across institutions and jurisdictions, without requiring organisations to rebuild their existing systems.
Logo files, brand guidelines, executive headshots and approved product imagery — everything you need to publish about The BioChain.
A short, honest list of where we have substantive expertise. If your story sits inside one of these, we'd be glad to talk.
Mark your email URGENT in the subject line — we route those directly to senior team members.